Uterine leiomyosarcoma in asian patients: Validation of the revised federation of gynecology and obstetrics staging system and identification of prognostic classifiers

Oncologist

Volumn 17, Issue 10, 2012, Pages 1286-1293

  Tan, Pei Shan ^a   Koh, Elisa ^c   Pang, Cindy ^c   Ong, Whee Sze ^d   Ngo, Lynette ^d   Soh, Lay Tin ^d   Quek, Richard ^d   Chay, Wen Yee ^d   Ho, Tew Hong ^c   Tay, Sun Kuie ^c   Chew, Sung Hock ^e   Lim Tan, Soo Kim ^e   Khoo Tan, Hs ^d   Lim, Sheow Lei ^e   Busmanis, Inny ^c   Goh, Liang Kee ^b,f   Chia, Yin Nin ^e   Chia, Whay Kuang ^d   Lim, Timothy ^e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^e KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

AJCC; FIGO; Leiomyosarcoma; Prognostic; Staging; Uterus

Indexed keywords

ADULT; AGED; ASIAN; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CELL INVASION; DEATH; FEMALE; HUMAN; LYMPH VESSEL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TUMOR VOLUME; UTERUS SARCOMA;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LEIOMYOSARCOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; UTERINE NEOPLASMS;

EID: 84868155870     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0124     Document Type: Review

References (20)

1. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas. Cancer 2008;112:820-830.
2. Pautier P, Genestie C, Rey A et al. Analysis of clinicopathological prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 2000;88:1425-1431.
3. Giuntoli RL, Metzinger DS, DiMarco CS et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy. Gynae Oncol 2003;89:460-469.
4. Mayerhofer K, Obermair A, Windbichler G et al. Leiomyosarcoma of the uterus:Aclinicopathologic multicentre study of 71 cases. Gynecol Oncol 1999;74:196-201.
5. Nordal RR, Kristensen GB, Kaern J et al. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol 1995;34:797-802.
6. Gadducci A, Landoni F, Sartori E et al. Uterine leiomyosarcoma: Analysis of treatment failure and survival. Gynecol Oncol 1996;62:25-32.
7. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009;104:179.
8. Berchuck A, Rubin SC, Hoskins WJ et al. Treatment of uterine leiomyosarcoma. Obstet Gynecol 1988;71: 845-850.
9. Soft tissue sarcoma. In: Edge SB, Byrd DR, Compton CC et al., eds. AJCC Cancer Staging Manual, 7th ed. New York: Springer, 2010:291-296.
10. Zivanovic O, Leitao MM, Iasonos A et al. Stagespecific outcomes of patients with uterine leiomyosarcoma: A comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems. J Clin Oncol 2009; 27:2066-2072.
11. Raut CP, Nucci MR, WangQet al. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer 2009;45:2818-2824.
12. Harrell F. Regression modeling strategies: With applications to linear models, logistic regression and survival analysis. New York: Springer, 2001.
13. Wang WL, Soslow R, HensleyMet al. Histopathological prognostic factors in stage I leiomyosarcoma of the uterus: a detailed analysis of 27 cases. Am J Surg Pathol 2011;35:522-529.
14. Naaman Y, Shveiky D, Ben-Shachar I et al. Uterine sarcoma: Prognostic factors and treatment evaluation. Isr Med Assoc J 2011;13:76-79.
15. Garg G, Shah JP, Liu JR et al. Validation of tumor size as staging variable in the revised International Federation of Gynaecology and Obstetrics stage i leiomyosarcoma. Int J Gynaecol Cancer 2010;20:1201-1206.
16. Pelmus M, Penault-Llorca F, Guillou L et al. Prognostic factors in early stage leiomyosarcoma of the uterus. Int J Gynaecol Cancer 2009;104:177-178.
17. Abeler VM, Royne O, Thoresen S et al. Uterine sarcomas in Norway: A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009;54:355-364.
18. Dinh TA, Oliva EA, Fuller AF et al. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol 2004;92:648-652.
19. Odicino F, Pecorelli S, Zigliani L et al. History of the FIGO cancer staging system. Int J Gynaecol Obstet 2008;101:205-210.
20. Zivanovic O, Lindsay MJ, Iasonos A et al. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer 2012; 118:660-669.